Additional references for "Heart disease and the elderly" by Michael Lye and Christina Donnellan. Heart 2000;84:560-6.

1. Pascaul J. Heart disease in older patients. Practitioner 1998;242:577-86.
2. Strehler B. Time, cells, and aging. New York: Academic, 1962.
3. Lie JT, Hammond PI. Pathology of the senescent heart: anatomic observations on 237 autopsy studies of patients 90 to 105 years old. Mayo Clin Proc 1988;63:552-64.
4. Davies MJ. Pathology of the conduction system. In: Caird FI, Dall JLC, Kennedy RD, eds. Cardiology in old age. New York: Plenum Press, 1976:57-9.
5. Otto CM, Lind BK, Kitzman DW, et al. Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly. N Engl J Med 1999;341:142-7.
6. Yin FCP. The aging vasculature and its effects on the heart. In: Weisfeldt ML, ed. The aging heart: its functions and response to stress. vol 12. New York: Raven Press, 1980:137-214.
7. Lipsitz LA, Jonsson PV, Marks BL, et al. Reduced supine cardiac volumes and diastolic filling rates in elderly patients with chronic medical conditions. Implications for postural blood pressure homeostasis. J Am Geriatr Soc 1990;38:103-7.
8. Ogawa T, Spina RJ, Martin III WJ, et al. Effects of aging, sex and physical training on cardiovascular responses to exercise. Circulation 1992;86:494-503.
9. Rodeheffer RJ, Gerstenblith G, Becker LC, et al. Exercise cardiac output is maintained with advancing age in healthy human subjects: cardiac dilatation and increased stroke volume compensate for a diminished heart rate. Circulation 1984;69:203-13.
10. Sollott SJ, Lakatta EG. Normal aging changes in the cardiovascular system. Cardiol Elderly 1993;1:349-58.
11. Gerstenblith G, Renlund DG, Lakatta EG. Cardiovascular response to exercise in younger and older men. Fed Proc 1987;46:1834-9.
12. Stratton JR, Cerqueira MD, Schwartz RS, et al. Differences in cardiovascular responses to isoproterenol in relation to age and exercise training in healthy men. Circulation 1992;86:504-12.
13. Manning WJ, Shannon RP, Santinga JA, et al. Reversal of changes in left ventricular diastolic filling associated with normal ageing using diltiazem. Am J Cardiol 1991;67:894-6.
14. Clarkson PBM, Wheeldon NM, Macleod C, et al. Effects of angiotensin-II and aldosterone on diastolic function in-vivo in normal man. Clin Sci 1994;87:397-401.
15. Luchi RJ, Snow E, Luchi JM. Left ventricular function in hospitalized geriatric patients. J Am Geriatr Soc 1982;30:700-5.
16. Sartori MP, Quinones MA, Kuo LC. Relation of Doppler-derived left ventricular filling parameters to age and radius/thickness ratio in normal and pathologic states. Am J Cardiol 1987;59:1179-82.
17. White W, Schulman P, Dey HM, et al. Effects of age and 24-hour ambulatory blood pressure on rapid left ventricular filling. Am J Cardiol 1989;63:1343-7.
18. Hachamovitch R, Wicker P, Capasso JM, et al. Alterations of coronary blood flow and reserve with aging in Fisher 344 rats. Am J Physiol 1989;256:H66-73.
19. Wei JY, Spurgeon HA, Lakatta EG. Excitation-contraction in rat myocardium: alterations with adult aging. Am J Physiol 1984;246:H784-91.
20. Wei JY. Use of calcium entry blockers in elderly patients. Special considerations. Circulation 1989;80:IV-171-77.
21. O�Keeffe ST, Lye M. Heart failure in the elderly: the same syndrome as the clinical trials? In: McMurray JJV, Cleland JGF, eds. Heart failure in clinical practice. London: Martin Dunitz, 1996:47-71.
22. Lye M. Access to advances in cardiology. Lancet 1997;350:1162-3.
23. O�Rourke RA, Chatterjee K, Wei JY. Cardiovascular heart disease in the elderly: coronary heart disease. J Am Coll Cardiol 1987;10(suppl A): 52A-6A.
24. O�Keeffe ST, Lye M. Signs in heart failure. In: Tallis RC, Fillit HM, Brocklehurst JC, eds. Textbook of geriatric medicine and gerontology, 5th ed. Edinburgh: Churchill Livingstone, 1998:281-6.
25. Wei JY. Congestive heart failure. In: Abrams WB, Berkow R, eds. Merck manual of geriatrics. West Point New York: Merck, 1990:380-6.
26. Levy DW, Lye M. Diuretics and potassium in the elderly. J R Coll Physicians Lond 1987;21:148-52.
27. The Captopril-Digoxin Multicenter Research Group. A placebo-controlled trial of captopril in refractory chronic congestive heart failure. J Am Coll Cardiol 1983;2:755-63.
28. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
29. Schwartz D, Kornowski R, Schwartz IF, et al. Prediction of renal impairment in elderly patients with congestive heart failure treated with captopril. Cardiovasc Drugs Ther 1996;10:75-9.
30. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the losartan heart failure survival study ELITE II. Lancet 2000;355:1582-7.
31. Jaeschke R, Oxman AD, Guyatt GH. To what extent do congestive heart failure patients in sinus rhythm benefit from digoxin therapy ? A systematic overview. Am J Med 1990;88:279-86.
32. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525-33.
33. Eberhardt RT, Frishman WH, Landau A, et al. Increased mortality in elderly individuals receiving digoxin therapy - results from the Bronx longitudinal aging study. Cardiol Elderly 1995;3:177-82.
34. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:303-10.
35. Baker DW, Konstam MA, Bottorff M, et al. Management of heart failure. I. Pharmacologic treatment. JAMA 1994;272:1361-6.
36. Gibbs CR, Davies MK, Lip GYH. ABC of heart failure - Management: digoxin and other inotropes, beta blockers, and antiarrhythmic and antithrombotic treatment. BMJ 2000;320:495-8.
37. King D. Cardiac cachexia in the elderly. Cardiol Elderly 1994;2:102-6.
38. King D, Smith ML, Chapman TJ, et al. Fat malabsorption in elderly patients with cardiac cachexia. Age Ageing 1996;25:144-9.
39. King D, Smith ML, Lye M. Gastrointestinal protein loss in elderly patients with cardiac cachexia. Age Ageing 1996;25:221-3.
40. Adams V, Jiang H, Yu J, et al. Apoptosis in skeletal myocytes of patients with chronic heart failure is associated with exercise intolerance. J Am Coll Cardiol 1999;33:959-65.
41. Stromberg A. Heart failure clinics. Heart 1998;80:426-7.
42. Erhardt L, Cline C. Heart failure clinics: a possible means of improving care. Heart 1998;80:428-9.
43. McMurray JJV, Stewart S. Nurse led, multidisciplinary intervention in chronic heart failure. Heart 1998;80:430-1.
44. Rodrigues EA, Lahiri A, Raftery EB. Improvement in left ventricular diastolic function in patients with stable angina after chronic treatment with verapamil and nicardipine. Eur Heart J 1987;8:624-9.
45. Cleland JGF, Tendera M, Adamus J, et al. Perindopril for elderly people with chronic heart failure: the PEP-CHF study. Eur J Heart Failure 1999;1:211-7.
46. McKee PA, Castelli WP, McNamara M, et al. The natural history of congestive heart failure : the Framingham Study. N Engl J Med 1971;285:1441-6.
47. Croft JB, Giles WH, Pollard RA, et al. Heart failure survival among older adults in the United States - a poor prognosis for an emerging epidemic in the Medicare population. Arch Intern Med 1999;159:505-10.
48. Kannel WB, Belanger AJ. Epidemiology of heart failure. Am Heart J 1991;121(pt 1):951-7.
49. Ghali JK, Cooper R, Ford E. Trends in hospitalization rates for heart failure in the United States, 1973-1986. Evidence for increasing population prevalence. Arch Intern Med 1990;150:769-73.
50. Eraker SA, Kirscht JP, Becker MH. Understanding and improving patient compliance. Ann Intern Med 1984;100:258-68.
51. Aronow WS. Cardiac risk factors: still important in the elderly. Geriatrics 1990;45:71-4.
52. Aronow WS. Cardiac risk factors: still important in the elderly. Geriatrics 1990;45:79-80.
53. Gillum RF. Trends in acute myocardial infarction and coronary disease death in the United States. J Am Coll Cardiol 1993;23:1273-7.
54. Waller BF, Roberts WC. Cardiovascular disease in the very elderly: analysis of necropsy patients aged 90 years or over. Am J Cardiol 1983;51:403-21.
55. Pathy MSJ. Clinical presentation of myocardial infarction in the elderly. Br Heart J 1967;29:190-9.
56. Rodstein M. The characteristics of non-fatal myocardial infarction in the aged. Arch Intern Med 1956;98:84-90.
57. Bayer AJ, Chadha JS, Farag RR, et al. Changing presentation of myocardial infarction with increaseing age. J Am Geriatr Soc 1986;34:263-6.
58. Kannel WB. Prevalence and clinical aspects of unrecognised myocardial infarction and sudden unexpected death. Circulation 1987;75:II4-5.
59. Nadelmann J, Frishman WH, Ooi WL, et al. Prevalence, incidence and prognosis of recognised and unrecognised myocardial infarction in persons aged 75 years or older - the Bronx aging study. Am J Cardiol 1990;66:533-7.
60. Yano K, Maclean CJ. The incidence and prognosis of unrecognized myocardial-infarction in the Honolulu, Hawaii, heart program. Arch Intern Med 1989;149:1528-32.
61. Sigurdsson E, Thorgeirsson G, Sigvaldason H, et al. Unrecognized myocardial infarction - epidemiology, clinical characteristics, and the prognostic role of angina-pectoris - the Reykjavik study. Ann Intern Med 1995;122:96-102.
62. Case RB, Moss AJ, Case N, et al. Living alone after myocardial-infarction - impact on prognosis. JAMA 1992;267:515-9.
63. Lambrew CT, Bowlby LJ, Rogers WJ, et al. Factors influencing the time to thrombolysis in acute myocardial infarction. Arch Intern Med 1997;157:2577-82.
64. Gurwitz JH, McLaughlin TJ, Willison DJ, et al. Delayed hospital presentation in patients who have had acute myocardial infarction. Ann Intern Med 1997;126:593-9.
65. Tresch DD, Brady WJ, Aufderheide TP, et al. Comparison of elderly and younger patients with out-of-hospital chest pain - clinical characteristics, acute myocardial infarction, therapy, and outcomes. Arch Intern Med 1996;156:1089-93.
66. Bueno H, L�pez-Palop R, Bermejo J, et al. In-hospital outcome of elderly patients with acute inferior myocardial infarction and right ventricular involvement. Circulation 1997;96:436-41.
67. Rich MW. Therapy for acute myocardial infarction. Clinics Geriatr Med 1996;12:141-68.
68. Fibrinolytic Therapy Trialists (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction. Collaborative overview of early mortality and major morbidity results from all randomized trials of more than 1000 patients. Lancet 1994;343:311-22.
69. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;ii:349-60.
70. The MIAMI Trial Research Group. Metoprolol in acute myocardial infarction (MIAMI). Low-molecular weight heparin during instability in coronary artery disease. Lancet 1996;347:561-8.
71. ISIS-1 (First International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. Lancet 1986;ii:57-66.
72. Swedberg K, Held P, Kjekshus J, et al. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. N Engl J Med 1992;327:678-84.
73. GISSI-3. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994;343:1115-22.
74. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997;337:447-52.
75. Rich MW, Bosner MS, Chung MK, et al. Is age an independent predictor of early and late mortality in patients with acute myocardial infarction ? Am J Med 1992;92:7-13.
76. Paul SD, O�Gara PT, Mahjoub ZA, et al. Geriatric patients with acute myocardial infarction: cardiac risk factor profiles, presentation, thrombolysis, coronary interventions, and prognosis. Am Heart J 1996;131:710-5.
77. Vaccarino V, Krumholz HM, Berkman LF, et al. Sex-differences in mortality after myocardial infarction - is there evidence for an increased risk for women. Circulation 1995;91:1861-71.
78. Rosenthal GE, Fortinsky RH. Differences in the treatment of patients with acute myocardial-infarction according to patient age. J Am Geriatr Soc 1994;42:826-32.
79. Krumholz HM, Radford MJ, Ellerbeck EF, et al. Aspirin for secondary prevention after acute myocardial infarction in the elderly: prescribed use and outcomes. Ann Intern Med 1996;124:292-8.
80. Frost PH, Davis BR, Burlando AJ, et al. Serum lipids and incidence of coronary heart disease: findings from the systolic hypertension in the elderly program (SHEP). Circulation 1996;94:2381-8.
81. Mittelmark MB, Psaty BM, Rautaharju PM, et al. Prevalence of cardiovascular diseases among older adults. The cardiovascular health study. Am J Epidemiol 1993;137:311-7.
82. Ruygrok PN, Agnew TM, Coverdale HA, et al. Coronary artery surgery in the elderly: long-term follow-up. Aust NZ J Med 1993;23:489-93.
83. Tan KH, Sulke N, Taub N, et al. Percutaneous transluminal coronary angioplasty in patients 70 years of age or older - 12 years experience. Br Heart J 1995;74:310-7.
84. Wheeldon NM, Tayler DI, Anagnostou E, et al. Screening for atrial fibrillation in primary care. Heart 1998;79:50-5.
85. Lawson-Matthew PJ, Ionescu A, McHugh P, et al. Evaluation of a protocol to select patients of all ages for cardioversion from atrial fibrillation. Age Ageing 1997;26:247-52.
86. Rawles JM. What is meant by a �controlled� ventricular rate in atrial fibrillation. Br Heart J 1990;63:157-61.
87. Boriani G, Biffi M, Branzi A, et al. Pharmacological treatment of atrial fibrillation: a review on prevention of recurrences and control of ventricular response. Arch Gerontol Geriatr 1998;27:127-39.
88. Kistler JP. Stroke in atrial fibrillation. Cardiol Elderly 1993;1:157-62.
89. Petersen P, Godtfredsen J. Risk factors for stroke in chronic atrial fibrillation. Eur Heart J 1988;9:291-4.
90. Lake FR, McCall MG, Cullen KJ, et al. Atrial fibrillation and mortality in an elderly poulation. Aust NZ J Med 1989;19:321-6.
91. Matsuo S, Nakamura Y, Kinoshita M. Warfarin reduces silent cerebral infarction in elderly patients with atrial fibrillation. Coronary Artery Disease 1998;9:223-6.
92. O�Connell JE, Gray CS. Atrial fibrillation and stroke prevention in the community. Age Ageing 1996;25:307-9.
93. Stroke Prevention in Atrial Fibrillation Investigators. Stroke prevention in atrial fibrillation study: final results. Circulation 1991;84:527-39.
94. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: stroke prevention in atrial fibrillation II study. Lancet 1994;343:687-91.
95. Gollub SB. Is intensive drug therapy appropriate for older patients? Lancet 1999;353:940-1.
96. Hutten BA, Lensing AWA, Kraaijenhagen RA, et al. Safety of treatment with oral anticoagulants in the elderly - a systematic review. Drugs Aging 1999;14:303-12.
97. Payne GE, Skehan JD. Issues in cardiac pacing: can agism be justified? Br Heart J 1994;72:102-3.
98. Cunningham AD, Rickards AF, Nathan AW. Trends in pacemaker implantation: is the UK the "poor man of Europe"? Br Heart J 1994;71(suppl): P59.
99. McComb JM, Bexton RS. Permanent pacemakers and the elderly - concerns, costs and benefits. Br Heart J 1995;74:9-10.
100. Linde-Edelstam C, Unden A-L, Orth-Gomer K, et al. Quality of life in patients treated with atrioventricular synchronous pacing compared to rate modulated ventricular pacing: a long term double-blind crossover study. PACE 1992;15:1467-76.
101. Burt VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the US adult population. Results from the 3rd national health and nutrition examination survey, 1988-1991. Hypertension 1995;25:305-13.
102. Ekpo EB, Ashworth IN, Fernando MU, et al. Prevalence of mixed hypertension, isolated systolic hypertension and isolated diastolic hypertension in the elderly population in the community. J Hum Hypertens 1994;8:539-43.
103. Kannel WB. Prospects for prevention of cardiovascular disease in the elderly. Prev Cardiol 1998;1:32-9.
104. Staessen JA, Gasowski J, Wang JG, et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 2000;355:865-72.
105. Glynn RJ, Field TS, Rosner B, et al. Evidence for a positive linear relation between blood pressure and mortality in elderly people. Lancet 1995;345:825-9.
106. MacMahon S, Rodgers A. The effects of blood-pressure reduction in older patients - an overview of 5 randomized controlled trials in elderly hypertensives. Clin Exper Hyperten 1993;15:967-78.
107. MacMahon S, Rodgers A. Blood pressure, antihypertensive treatment and stroke risk. J Hypertens 1994;12:S5-14.
108. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial. Lancet 1998;351:1755-62.
109. Beckett NS, Fletcher AE, Bulpitt CJ. The rationale for the hypertension in the very elderly trial (HYVET). Eur Heart J 1999;1:P13-6.